| Literature DB >> 26693341 |
Adrienn Tarr1, Stephan Stoebe1, Jan Tuennemann1, Zsuzsanna Baka2, Dietrich Pfeiffer1, Albert Varga3, Andreas Hagendorff1.
Abstract
The aim of the present study was to find out whether early cardiac changes in patients receiving chemotherapy can be detected by the conventional and deformation parameters of 2D and 3D echocardiography. Twenty-five healthy subjects with normal regional left ventricular function (group 1) and 25 patients receiving chemotherapy (group 2) underwent 2D and 3D transthoracic echocardiography (Toshiba Artida Medical System). All patients (group 2) were examined before and during cardiotoxic chemotherapy at a 3-month follow-up. Left ventricular volumes, ejection fraction, muscle mass, global longitudinal, global radial, global circumferential strain, and rotation were analyzed with 2D and 3D echocardiography, while twist and time-to-peak-intervals were analyzed with 3D echocardiography. For left ventricular volumes and muscle mass, no significant differences were seen between the two study groups (P<0.05). According to our results, myocardial dysfunction induced by cardiotoxic chemotherapy can be detected by 2D global radial strain. Detecting myocardial dysfunction by global longitudinal and circumferential strain requires more than 3 months follow-up. Changes in rotation, twist or time-to-peak intervals could not be verified at the 3-month follow-up in the present study. 2D global radial strain seems to be the most sensitive and robust parameter to detect early myocardial damage during chemotherapy. 3D echocardiography is not yet an established method to detect myocardial damage in clinical practice due to lower spatial and temporal resolution.Entities:
Keywords: 2D speckle tracking echocardiography; 3D speckle tracking echocardiography; cancer; cardiotoxicity; chemotherapy
Year: 2015 PMID: 26693341 PMCID: PMC4676474 DOI: 10.1530/ERP-14-0084
Source DB: PubMed Journal: Echo Res Pract ISSN: 2055-0464
Clinical data of both cohorts.
|
|
|
|
|
|---|---|---|---|
| Age | 45±12 | 63±15 | 0.37 |
| Male | 16 (64%) | 11 (44%) | 0.13 |
| Female | 9 (36%) | 14 (56%) | 0.13 |
| Smoker | 6 (24%) | 7 (28%) | 0.71 |
| Alcohol consumption | 0 (0%) | 0 (0%) | NS |
| Arterial hypertension | 5 (20%) | 11 (44%) | 0.41 |
| Coronary heart disease | 0 (0%) | 2 (8%) | 0.15 |
| Pulmonary embolism | 0 (0%) | 1 (4%) | 0.31 |
| Diabetes mellitus type 2 | 0 (0%) | 5 (20%) | 0.16 |
| Peripheral arterial disease | 0 (0%) | 2 (8%) | 0.15 |
| Hypercholesterinemia | 0 (0%) | 2 (8%) | 0.15 |
| Chronic obstructive pulmonary disease | 0 (0%) | 4 (16%) | 0.34 |
| β-blocker therapy | 10 (0%) | 7 (28%) | 0.29 |
| Ace-inhibitor therapy | 11 (0%) | 5 (20%) | 0.29 |
| Calcium antagonist therapy | 0 (0%) | 2 (8%) | 0.15 |
Comparison of conventional parameters between groups 1 and 2 and between different time points (group 2 before and during chemotherapy); *P value <0.05.
|
|
|
| |
|---|---|---|---|
| 3D LVEF (%) | 57±9 | 50±16*,
| 49±7*,
|
| 3D LVEDV (ml) | 108±36 | 113±22 | 108±28 |
| 3D LVESV (ml) | 47±25 | 56±14 | 55±16 |
| 3D muscle mass (g) | 133±24 | 150±29 | 149±27 |
LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume.
Comparison between groups 1 and 2 (before chemotherapy).
Comparison between groups 1 and 2 (during chemotherapy).
Comparison of deformation parameters between groups 1 and 2 and between different time points (group 2 before and during chemotherapy); *P value <0.05.
|
|
|
| |
|---|---|---|---|
| 3D global radial strain (%) | 34±16.67 | 28±12.75 | 26±14.48 |
| 3D global circumferential strain (%) | −28±1.71 | −21±4.50*,
| −22±4.70*,
|
| 3D global longitudinal strain (%) | −14±1.52 | −13±2.55 | −12±2.23 |
| 2D global radial strain (%) | 23±9.38 | 28±10.56*,
| 21±11.53*,
|
| 2D global circumferential strain (%) | −23±3.77 | −21±7.82 | −18±8.21*,
|
| 2D global longitudinal strain (%) | −16±2.90 | −15±4.20 | −14±4.56*,
|
| 2D rotation (°) | 1.3±0.27 | 1,02±0.24 | 0,82±0,18 |
| 3D rotation (°) | 3.5±0.28 | 3.4±2.17 | 3.3±2.34 |
| 3D twist (°/cm) | 3.5±2.24 | 4.2±2.68 | 4.4±2.88 |
| 3D time-to-peak interval (radial) (ms) | 402±79.09 | 402±65.90 | 389±80.32 |
| 3D time-to-peak interval (circumferential) (ms) | 359±70.17 | 382±45.03 | 380±76.74 |
| 3D time-to-peak interval (longitudinal) (ms) | 375±68.28 | 379±55.09 | 355±65.71 |
Comparison between groups 1 and 2 (before chemotherapy).
Comparison between groups 1 and 2 (during chemotherapy).
Comparison between group 2 before and group 2 during chemotherapy.
Figure 12D parasternal short axis view at the level of the mitral valve (c) and the corresponding radial strain curves (f) before chemotherapy are shown. Below the corresponding view (i) and radial strain curves (l) during chemotherapy after 3 months are shown. The peak radial strain at the beginning of the chemotherapy is 39.4% and after 3 month is 42.1%.
Figure 22D parasternal short axis view at the level of the left ventricular apex (a) and the corresponding circumferential strain curves (d) before chemotherapy are shown. Below the corresponding view (g) and circumferential strain curves (j) during chemotherapy after 3 months are shown. The peak circumferential strain at the beginning of the chemotherapy is −20.5%) and after 3 months is −18.5%.
Figure 32D apical long axis view (a) and the corresponding longitudinal strain curves (d) before chemotherapy are shown. Below the corresponding view (g) and longitudinal strain curves (j) during chemotherapy after 3 months are shown. The peak longitudinal strain at the beginning of the chemotherapy is −24.2% and after 3 months is −25.6%.
Figure 42D apical two-chamber view (b) and the corresponding longitudinal strain curves (e) before chemotherapy are shown. Below the corresponding view (h) and longitudinal strain curves (k) during chemotherapy after 3 months are shown. The peak longitudinal strain at the beginning of the chemotherapy is −20.6% and after 3 months is −20.5%.
Figure 52D apical four-chamber view (c) and the corresponding longitudinal strain curves (f) before chemotherapy are shown. Below the corresponding view (i) and longitudinal strain curves (l) during chemotherapy after 3 months are shown. The peak longitudinal strain at the beginning of the chemotherapy is −17.7% and after 3 months is −24.5%.
Figure 63D radial strain curves of a patient before (a) and during (b) chemotherapy after 3 months are shown. 3D circumferential strain curves of a patient before (c) and during (d) chemotherapy after 3 months are shown. 3D longitudinal strain curves of a patient before (e) and during (f) chemotherapy after 3 months are shown.